Amundi Has $685,000 Holdings in Certara, Inc. (NASDAQ:CERT)

Amundi increased its position in shares of Certara, Inc. (NASDAQ:CERT - Free Report) by 222.8% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 62,167 shares of the company's stock after purchasing an additional 42,907 shares during the quarter. Amundi's holdings in Certara were worth $685,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the company. Blue Trust Inc. increased its position in shares of Certara by 20.9% during the 4th quarter. Blue Trust Inc. now owns 4,747 shares of the company's stock worth $56,000 after purchasing an additional 822 shares in the last quarter. Nicolet Advisory Services LLC increased its position in shares of Certara by 6.6% during the 3rd quarter. Nicolet Advisory Services LLC now owns 24,831 shares of the company's stock worth $273,000 after purchasing an additional 1,531 shares in the last quarter. KBC Group NV increased its position in shares of Certara by 48.2% during the 3rd quarter. KBC Group NV now owns 4,873 shares of the company's stock worth $57,000 after purchasing an additional 1,584 shares in the last quarter. Venturi Wealth Management LLC increased its position in shares of Certara by 839.1% during the 4th quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company's stock worth $30,000 after purchasing an additional 2,509 shares in the last quarter. Finally, Atria Investments Inc increased its position in shares of Certara by 21.6% during the 3rd quarter. Atria Investments Inc now owns 19,743 shares of the company's stock worth $231,000 after purchasing an additional 3,501 shares in the last quarter. Institutional investors and hedge funds own 73.96% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. TD Cowen assumed coverage on shares of Certara in a research report on Thursday, February 27th. They set a "buy" rating and a $16.00 target price for the company. William Blair restated a "market perform" rating on shares of Certara in a research report on Thursday, February 27th. Stephens restated an "overweight" rating and issued a $17.00 price objective on shares of Certara in a research report on Thursday, February 27th. Finally, Barclays raised their price objective on shares of Certara from $12.00 to $13.00 and gave the company an "equal weight" rating in a research report on Friday, February 28th. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $15.83.

Certara Trading Up 1.2 %

Shares of NASDAQ CERT traded up $0.13 during mid-day trading on Friday, hitting $10.73. The company's stock had a trading volume of 1,763,236 shares, compared to its average volume of 1,012,507. The stock has a market cap of $1.73 billion, a price-to-earnings ratio of -53.65, a price-to-earnings-growth ratio of 9.29 and a beta of 1.60. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. Certara, Inc. has a one year low of $9.41 and a one year high of $19.18. The company's fifty day simple moving average is $12.55 and its 200-day simple moving average is $11.49.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.